Genetic products company,
), inked a 'Powered by Affymetrix' ("PbA") Program agreement with
Korea-based biotechnology company, DNA Link Inc. Following the
terms of the deal, DNA Link acquired a global license to use
Affymetrix's GeneChip System 3000Dx v.2 along with other
microarray technologies to develop a forensic test for human
AFFYMETRIX INC (AFFX): Free Stock Analysis
ALKERMES INC (ALKS): Free Stock Analysis
ILLUMINA INC (ILMN): Free Stock Analysis
(RHHBY): ETF Research Reports
To read this article on Zacks.com click here.
The GCS 3000Dx v.2 from Affymetrix is a second-generation
solution for DNA and RNA analysis. It has received the U.S. Food
and Drug Administration ("FDA") approval as well as the European
CE Mark for in vitro diagnostic ("IVD") uses. The system has also
been cleared by the Korean FDA.
DNA Link intends to combine Affymetrix's leading GeneChip
technology with its cutting-edge forensic test, AccuID Chip, to
develop innovative molecular diagnostic tests for personalized
healthcare in the field of genomics.
Earlier, in Aug 2012, Affymetrix had signed a PbA Program
agreement with a Singapore-based molecular diagnostics company,
PathGEN Dx Pte. Ltd. Apart from PathGEN Dx, the company shares
its technology with Roche Diagnostics, a unit of
Roche Holdings Ltd.
), and Pathwork Diagnostics.
Affymetrix is a leading provider of microarray-based products and
services to the global research community. Apart from
), it is one of the two major providers of microarray
technologies, primarily serving the field of genetic research.
The latest agreement is in accordance with Affymetrix's strategy
to expand its customer base through strategic alliances.
Moreover, the company is pursuing a number of strategies
(including acquisitions and expansion into new markets) aimed at
expanding its top line.
The 'Powered by Affymetrix' Program is an initiative by
Affymetrix, which allows other companies to gain access to its
GeneChip technology in order to develop new microarray products
and solutions. The collaboration with DNA Link marks Affymetrix's
first partnership venture in Korea. The agreement further allows
Affymetrix's other PbA partners to enter Korea's personalized
However, research and development spending by Affymetrix's
customers have fallen considerably due to a weak macroeconomic
environment coupled with stringent government actions including
The company currently carries a Zacks Rank #3 (Hold).
), carrying a Zacks Rank #1 (Strong Buy), is expected to do well
in the Medical-Biomed/Gene industry.